Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

Cited by (444)

Items 301–400 of 444

1. Alternative vaccine delivery methods
   Bruce G. Weniger, Mark J. Papania · 2008 · Elsevier eBooks
2. Toll-like receptor modulation in cardiovascular disease: a target for intervention?
   Gábor Földes, Stephan von Haehling, Stefan D. Anker · 2006 · Expert Opinion on Investigational Drugs
3. Breaking the barriers in effective and safe Toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy
   Yaoqi Li, Yitian Chen, Yongan Tang, Tao Yang, Ping Zhou, Liyan Miao, Huabing Chen, Yibin Deng · 2025 · Journal of Controlled Release
4. Targeting prion proteins in neurodegenerative disease
   Sabine Gilch, Carmen I. Nussbaum-Krammer, Hermann M. Schätzl · 2008 · Expert Opinion on Biological Therapy
5. The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8+ T-cell responses in vitro
   Laura Papagno, Nozomi Kuse, Anna Lissina, Emma Gostick D, David A. Price, Victor Appay, Francesco Nicoli · 2020 · Scientific Reports
6. IL-18 Binding Protein–Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome
   Mathilde Harel, Sébastien Fauteux‐Daniel, Emiliana Rodriguez, Gaby Palmer, Cem Gabay · 2023 · The Journal of Immunology
7. Enhancement of immunomodulatory activity by liposome-encapsulated natural phosphodiester bond CpG-DNA in a human B cell line
   Dongbum Kim, Jae-Won Rhee, Sanghoon Kwon, Young-Eun Kim, Soo‐Young Choi, Jinseu Park, Younghee Lee, Hyung‐Joo Kwon · 2010 · BMB Reports
8. Adoptive Transfer of T Lymphocytes Sensitized against the Prion Protein Attenuates Prion Invasion in Scrapie-Infected Mice
   Pauline Gourdain, Sylvie Grégoire, Saci Iken, Véronique S. Bachy, Gauthier Dorban, Thomas Chaigneau, Hanna Dêbiec, Anne‐Sophie Bergot, Isabelle Renault, Pièrre Aucouturier et al. · 2009 · The Journal of Immunology
9. Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists
   Richard Kamgang, M Inês Pascoal Ramos, Lurdes Rodrigues Duarte, Mascia Ghielmetti, Marina A. Freudenberg, Clemens A. Dahinden, Elisabetta Padovan · 2008 · Medical Microbiology and Immunology
10. ERK is involved in the regulation of CpG ODN 2395 on the expression levels of anti-lipopolysaccharide factors in Chinese mitten crab, Eriocheir sinensis
    Shu Huang, Yuhan Ma, Fengchi Wang, Jiaming Li, Zhichao Yang, Yusheng Jiang, Xi Chen, Shengyang Hu, Qilin Yi · 2022 · Fish & Shellfish Immunology
11. Systemic Toll-Like Receptor Ligation and Selective Killing of Dendritic Cell Subsets Fail To Dissect Priming Pathways for Anti-Vaccinia Virus CD8 + T Cells
    Yik Chun Wong, Stewart A. Smith, David C. Tscharke · 2013 · Journal of Virology
12. Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context
    Kerstin Kapp, Jacqueline Schneider, Lisa Schneider, Nadine Gollinge, Stefanie Jänsch, Matthias Schroff, Burghardt Wittig, Christiane Kleuss · 2016 · Immunity Inflammation and Disease
13. Revolutionary impact of nanovaccines on immunotherapy
    Mohammad‐Ali Shahbazi, Hélder A. Santos · 2014 · European Journal of Molecular & Clinical Medicine
14. Topical CpG Adjuvantation of a Protein-Based Vaccine Induces Protective Immunity to Listeria monocytogenes
    Wing Ki Cheng, Kathleen Wee, Tobias R. Kollmann, Jan Peter Dutz · 2014 · Clinical and Vaccine Immunology
15. Immunomodulation by inactivated Orf virus (ORFV) - therapeutic potential
    Olaf Weber, Percy Alexander Knolle, Hans‐Dieter Volk · 2007 · Birkhäuser Basel eBooks
16. Intratumoral Administration of Secondary Lymphoid Chemokine and Unmethylated Cytosine-phosphorothioate-guanine Oligodeoxynucleotide Synergistically Inhibits Tumor Growth in Vivo
    So Mi Oh, Keunhee Oh, Dong‐Sup Lee · 2011 · Journal of Korean Medical Science
17. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma
    Christian Karime, Jing Wang, Gregory J. Woodhead, Kabir Mody, Charles T. Hennemeyer, Mitesh J. Borad, Daruka Mahadevan, Sreenivasa Rao Chandana, Hani M. Babiker · 2021 · Expert Opinion on Investigational Drugs
18. Immune Interventions of Human Diseases through Toll-Like Receptors
    Cevayir Coban, Ken J. Ishii, Shizuo Akira · 2009 · Advances in experimental medicine and biology
19. An attenuated EIAV strain and its molecular clone strain differentially induce the expression of Toll-like receptors and type-I interferons in equine monocyte-derived macrophages
    Jian Ma, Shanshan Wang, Yuezhi Lin, Haifang Liu, Huamian Wei, Cheng Du, Xuefeng Wang, Jian-hua Zhou · 2013 · Veterinary Microbiology
20. Broad-Spectrum Drugs Against Viral Agents
    Mary Christopher, Jonathan P. Wong · 2008 · International Journal of Molecular Sciences
21. Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.
    Ensieh Golali, Mahmoud Reza Jaafari, Ali Khamesipour, Azam Abbasi, Zahra Saberi, Ali Badiee · 2012 · Europe PMC (PubMed Central)
22. Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families
    Céline Robert-Tissot, Vera Leandra Rüegger, Valentino Cattori, Marina Luisa Meli, Barbara Riond, Peter F. Moore, Monika Engels, Marco Franchini, Regina Hofmann‐Lehmann, Hans Lutz · 2012 · Veterinary Research
23. The immunosuppressive effects of continuous CpG ODNs stimulation in chinese mitten crab, Eriocheir sinensis
    Zhao, D, L Song, Renzhi Liu, Zhongxiu Liang, Lihui Wang, Mingzhe Sun, Beiwei Zhu · 2018 · Invertebrate survival journal
24. Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice
    Teppei Matsuda, Kazuki Misato, Shigeyuki Tamiya, Yasuhiro Akeda, Ikuhiko Nakase, Etsushi Kuroda, Shokichi Takahama, Motohiro Nonaka, Takuya Yamamoto, Michiko N. Fukuda et al. · 2022 · iScience
25. Combined use of chemically modified nucleobases and nanostructured DNA for enhanced immunostimulatory activity of CpG oligodeoxynucleotide
    Yuki Araie, Shozo Ohtsuki, Soyoung Park, Makoto Nagaoka, Keisuke Umemura, Hiroshi Sugiyama, Kosuke Kusamori, Yuki Takahashi, Yoshinobu Takakura, Makiya Nishikawa · 2020 · Bioorganic & Medicinal Chemistry
26. Starch-based NP act as antigen delivery systems without immunomodulating effect
    François Fasquelle, Laurent Dubuquoy, Didier Betbeder · 2022 · PLoS ONE
27. A safety study of a B‐class CpG ODN in Sprague–Dawley rats
    Li Liu, Lianzhong Shen, Xiaomeng Liu, Yongli Yu, Yinzeng Li, Liying Wang, Chunyan He, Jianning Sun, Bo Li · 2011 · Journal of Applied Toxicology
28. Coadministration of antigen-conjugated and free CpG: Effects of in vitro and in vivo interactions in a murine model
    Melinda Herbáth, Zsuzsanna Szekeres, Dorottya Kövesdi, Krisztián Papp, Anna Erdei, József Prechl · 2014 · Immunology Letters
29. Enhancing the osteogenic capacity of MG63 cells through N-isopropylacrylamide-modified polyethylenimine-mediated oligodeoxynucleotide MT01 delivery
    Yi Zheng, Chongtao Lin, Xu Hou, Ning Ma, Wenwen Yu, Xiaowei Xu, Yixin Lou, Hongbo Fei, Yuqin Shen, Xinhua Sun · 2017 · RSC Advances
30. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
    Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig, Manuel Schmidt · 2019 · Journal for ImmunoTherapy of Cancer
31. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes
    Takayuki Nakagawa, Tetsuya Tanino, Motoyasu Onishi, Soichi Tofukuji, Takayuki Kanazawa, Yukichi Ishioka, Takeshi Itoh, Akira Kugimiya, Kazufumi Katayama, Takuya Yamamoto et al. · 2021 · Frontiers in Immunology
32. Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs
    Dongbum Kim, Jinwon Jung, Younghee Lee, Hyung‐Joo Kwon · 2011 · Molecular Immunology
33. Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist
    Zuzanna Makowska, Tanja Blumer, François H.T. Duong, Nicola La Monica, Ekambar R. Kandimalla, Markus Hermann Heim · 2012 · Journal of Hepatology
34. Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity
    Yarong Zeng, Yifan Yin, Jialin Xu, Rong Su, Sibo Zhang, Feng Han, Yufang Li, Xueqing Zhu, Ciying Qian, Feihong Zou et al. · 2025 · Journal of Nanobiotechnology
35. Effects of oligodeoxynucleotide with CCT repeats on chronic graft versus host disease induced experimental lupus nephritis in mice
    Chunyan He, Lei Zhou, Ran Sun, Tiesuo Zhao, Yongsheng Zhang, Yao Shi Fu, Liying Wang, Yongli Yu · 2011 · Clinical Immunology
36. In vitro test system for evaluation of immune activation potential of new single‐stranded DNA‐based therapeutics
    Meltem Avci‐Adali, Ludmilla Hann, Tatjana Michel, Heidrun Steinle, Sandra Stoppelkamp, Katharina Stang, Miwako Narita, Christian Schlensak, Hans Peter Wendel · 2014 · Drug Testing and Analysis
37. Do cytosine guanine dinucleotide (CpG) fragments induce vasoactive neuropeptide mediated fatigue-related autoimmune disorders?
    Donald Staines · 2005 · Medical Hypotheses
38. Immunomodulatory consequences of ODN CpG-polycation complexes
    Charalambos D. Partidos, Johan Hoebeke, Sébastien Wieckowski, Olivier Chaloin, Alberto Bianco, Emmanuel Moreau, Jean‐Paul Briand, Claude Des̀granges, Sylviane Muller · 2009 · Methods
39. Extracellular Release of CD11b by TLR9 Stimulation in Macrophages
    Dongbum Kim, Te Ha Kim, Guang Jer Wu, Byoung Kwon Park, Ji-Hee Ha, Yong‐Sung Kim, Keunwook Lee, Younghee Lee, Hyung‐Joo Kwon · 2016 · PLoS ONE
40. Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities
    Nobutaka Hanagata, Xianglan Li, Minhua Chen, Jie Li, Shinya Hattori · 2017 · International Journal of Nanomedicine
41. Recent developments in mucosal vaccines against prion diseases
    Suehiro Sakaguchi, Takeshi Arakawa · 2007 · Expert Review of Vaccines
42. Immunostimulatory oligonucleotides in therapy of allergic diseases
    Maciej Jakub Lazarczyk, Katarzyna Grzela, Tomasz Grzela · 2005 · Expert Opinion on Biological Therapy
43. Enantiomer-dependent and modification-free DNA matrix as an adjuvant for subunit vaccines against SARS-CoV-2 or pneumococcal infections
    Cuifeng Li, Yuxin Li, Bini Zhou, Tong Li, Xiaohui Wei, Kun Chen, Wenlong Chen, Ziwei Shi, Xiaobin Dai, Jiachen Zhang et al. · 2025 · Nature Biomedical Engineering
44. Innovative microbial strategies in atopic dermatitis
    Jing Ma, Yi‐Ting Fang, Jinxing Hu, Shiqi Li, Lilian Zeng, Siyi Chen, Zhifeng Li, Ruiling Meng, Xingfen Yang, Fenglin Zhang et al. · 2025 · Frontiers in Immunology
45. Encapsidated-CpG ODN enhances immunogenicity of porcine circovirus type 2 virus-like particles
    Payuda Hansoongnern, Nantawan Phecharat, Ketkaew Wasanasuk, Wantanee Tommeurd, Penpitcha Chankeeree, Chalermpol Lekcharoensuk, Ploypailin Semkum, Sunan Pinitkiatisakul, Porntippa Lekcharoensuk · 2022 · Veterinary Microbiology
46. The presence of MOMA‐2+ macrophages in the outer B cell zone and protection of the splenic micro‐architecture from LPS‐induced destruction depend on secreted IgM
    Michael Bernhard Fischer, Beate M. Rüger, Christine Vaculik, Alexander Becherer, Wolfgang Wadsak, Genya Yanagida, Udo M Losert, Jianzhu Chen, Michael C. Carroll, Martha Marianne Eibl · 2007 · European Journal of Immunology
47. Advanced DNA nanomachines: Strategies and bioapplications
    Fariba Mollarasouli, Ulya Badıllı, Nurgül K. Bakırhan, Síbel A. Özkan, Yalçın Özkan · 2020 · Journal of Drug Delivery Science and Technology
48. Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice
    Juergen Tepel, O. Dagvadorj, Matthias Kapischke, Bence Sipos, Alexander Leins, B. Kremer, Holger Kalthoff · 2005 · International Journal of Colorectal Disease
49. Analysis by Flow Cytometry of B-Cell Activation and Antibody Responses Induced by Toll-Like Receptors
    Egest James Pone · 2016 · Methods in molecular biology
50. Co-delivery of antigen and adjuvant by site-specific conjugation to dendritic cell-targeted Fab fragments potentiates T cell responses
    Zacharias Wijfjes, Iván Ramos‐Tomillero, Camille M. Le Gall, Eric A. W. van Dinther, Frederique Turlings, René Classens, Saikat Manna, Duco van Dalen, Ruud J. R. W. Peters, Kayleigh Schouren et al. · 2025 · RSC Chemical Biology
51. Tripartite Interaction of Epigenetic Regulation, Brain Aging, and Neuroinflammation: Mechanistic Insights and Therapeutic Implications
    Shenghui Mi, Hideyuki Nakashima, Kinichi Nakashima · 2025 · Epigenomes
52. Synergistic Effects of Metal–Organic Nanoplatform and Guanine Quadruplex-Based CpG Oligodeoxynucleotides in Therapeutic Cancer Vaccines with Different Tumor Antigens
    Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki, Nobutaka Hanagata · 2024 · Vaccines
53. Rational Design of DNA Nanostructures as TLR9 Agonists
    Chunfa Chen, Cheng Tian, Zhuoer Jin, Yuandong Wen, Xiaoyu Xia, Qiao Ren, Cheng Zhi Huang, Hua Zuo · 2025 · Biomacromolecules
54. Distinct roles of IL-18 and IL-1β in murine model of macrophage activation syndrome
    Mao Mizuta, Natsumi Inoue, Masaki Shimizu, Naoto Sakumura, Tadafumi Yokoyama, Rie Kuroda, Yasuhiro Ikawa, Naotoshi Sugimoto, Kenichi Harada, Akihiro Yachie et al. · 2023 · Journal of Allergy and Clinical Immunology
55. Type I Interferon in HIV Treatment: From Antiviral Drug to Therapeutic Target
    Adriano Boasso · 2009 · HIV Therapy
56. Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART
    Albert Font-Haro, Vaclav Janovec, Tomáš Hofman, Ladislav Machala, David Jilich, Zora Mělková, Jan Weber, Kateřina Trejbalová, Ivan Hirsch · 2018 · Viruses
57. Intrahepatic DNA Vaccination: Unexpected Increased Resistance Against Murine Cysticercosis Induced by Non-specific Enhanced Immunity
    Carmen Cruz-Revilla, Adam M. Sonabend, Gabriela Rosas, Andrea Toledo, Gabriela Meneses, Fernando López‐Casillas, B. Hernández, Gladis Fragoso, Edda Sciutto · 2006 · Journal of Parasitology
58. Innate Immunity
    Lars Eckmann · 2006 · Elsevier eBooks
59. Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3
    Tiesuo Zhao, Xiuli Wu, Dandan Song, Mingli Fang, Sheng Guo, Peiyin Zhang, Liying Wang, Liping Wang, Yongli Yu · 2012 · International Immunopharmacology
60. Effects of lipopolysaccharide and CpG-DNA on burn-induced skin injury
    Byoung-Kwon Park, Dongbum Kim, Sunhee Cho, Jae-Nam Seo, Jae‐Bong Park, Yong-Sun Kim, Ihn-Geun Choi, Hyeok-Yil Kwon, Younghee Lee, Hyung‐Joo Kwon · 2011 · BMB Reports
61. PEGylated meloxicam-loaded nanocapsules reverse in vitro damage on caspase activity and do not induce toxicity in cultured human lymphocytes and mice
    Vivian Shinobu Kishimoto Nishihira, Barbara Dotto Fontana, Francine R. Ianiski, Hemilaine S. de Almeida, Christopher P. Posser, Juliane B. Dias, Crystian B. Parodi, Manoela Marchezan Piva, Anderson Gris, Ricardo E. Mendes et al. · 2018 · Biomedicine & Pharmacotherapy
62. Novel Toll-Like Receptor 9 Agonist Derived from Cryptococcus neoformans Attenuates Allergic Inflammation Leading to Asthma Onset in Mice
    Kaori Dobashi-Okuyama, Kazuyoshi Kawakami, Tomomitsu Miyasaka, Ko Sato, Keiko Ishii, Kaori Kawakami, Chiaki Masuda, Syugo Suzuki, Jun Kasamatsu, Hideki Yamamoto et al. · 2020 · International Archives of Allergy and Immunology
63. Treatment with phosphodiester CpG-ODN ameliorates atopic dermatitis by enhancing TGF-β signaling
    Won-Kook Ham, Eunjung Lee, Myung Shin Jeon, Hae-Young Kim, Gaurav Agrahari, Eun-Joo An, Chul Hwan Bang, Doo‐Sik Kim, Tae‐Yoon Kim · 2021 · BMB Reports
64. Sgp3 and Sgp4 control expression of distinct and restricted sets of xenotropic retroviruses encoding serum gp70 implicated in murine lupus nephritis
    Masao Kihara, Valérie Leroy, Lucie Baudino, Leonard H. Evans, Shozo Izui · 2011 · Journal of Autoimmunity
65. MIDGE Vectors and dSLIM Immunomodulators: DNA‐based Molecules for Gene Therapeutic Strategies
    Manuel Schmidt, Barbara Volz, Burghardt Wittig · 2005 · Wiley eBooks
66. Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection
    Byoung Kwon Park, Dongbum Kim, Guang Jer Wu, Song Hee Choi, Doo‐Sik Kim, Younghee Lee, Hyung‐Joo Kwon · 2014 · Journal of the Korean Society for Applied Biological Chemistry
67. Treatment by CpG or Flt3-ligand does not affect mouse susceptibility to BSE prions
    Grégory R G Doré, Claude Leclerc, Françoise Lazarini · 2008 · Journal of Neuroimmunology
68. Progress in prion vaccines and immunotherapies
    Jennifer K. Griffin, Neil R. Cashman · 2005 · Expert Opinion on Biological Therapy
69. Optimized Systemic Dosing with CpG DNA Enhances Dendritic Cell-Mediated Rejection of a Poorly Immunogenic Mammary Tumor in BALB/c Mice
    Quan Cai, Lyubov Kublo, Rachel L. Cumberland, William E. Gooding, Joseph Baar · 2009 · Clinical and Translational Science
70. Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy
    Huan Gong, J. Daniel Griffin, Chad E. Groer, Xiaoqing Wu, Mengyue Li, Moustafa M. Abdelaziz, Liang Xu, Marcus Laird Forrest, Cory J. Berkland · 2025 · Drug Delivery and Translational Research
71. Adjuvant-free parenterally injectable vaccine platform that harnesses previously induced IgG as an antigen delivery carrier
    Atsushi Kawai, Haruki Hirata, Nagisa Tokunoh, Chikako Ono, Yoshiharu Matsuura, Toshiro Hirai, Yasuo Yoshioka · 2024 · Biochemical and Biophysical Research Communications
72. Effects of a P-class CpG-ODN administered by intramuscular injection on plasma cytokines and on white blood cells of healthy horses
    Irène Tosi, Fabrice Bureau, Frédéric Farnir, Jean Marie Denoix, Pierre M. Lekeux, Tatiana Art · 2018 · Veterinary Immunology and Immunopathology
73. Nanopharmacology
    Zoraida P. Aguilar · 2012 · Elsevier eBooks
74. Nanotechnology for Cancer Vaccine Delivery
    Samar Ismail Hamdy, Aws Alshamsan, John Samuel · 2008 · Springer eBooks
75. The contribution of the immune system to prion diseases
    Gianluigi Forloni · 2004 · Drug Discovery Today Disease Mechanisms
76. Construction of Functional DNA Nanostructures for Theranostic Applications
    Jiang Li, Li Fan, Hao Pei, Lihua Wang, Qing Huang, Chunhai Fan · 2015 · Wiley eBooks
77. Prions of Humans and Animals
    Adriano Aguzzi · 2010 · Wiley eBooks
78. Serum Alters the Uptake and Biologic Activity of CpG Oligodeoxynucleotides in B Cell Chronic Lymphocytic Leukemia
    Bernd Jahrsdörfer, Sue E Blackwell, James E. Wooldridge, Christiana M. Taylor, George J. Weiner · 2005 · Oligonucleotides
79. Liposome-Encapsulated Adjuvants are Potent Inducers of Antigen-Specific T-Cells in Vivo
    Abdo Konur, Andreas Graser, Inga Klamp, Sebastian Kreiter, Abderraouf Selmi, Mustafa Diken, Christoph Huber, Özlem Türeci, Uğur Şahin · 2008 · The Open Cancer Journal
80. Toll-like Receptors (TLRs) And Prion Disease: Relevance To Pathology And Novel Therapy
    Okom Ofodile · 2011
81. Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines
    Eva Zupančič, Carina Peres, Ana I. Matos, Joao Lopes, João Nuno Moreira, Rogério S. Gaspar, Helena F. Florindo · 2015 · Current Topics in Medicinal Chemistry
82. N-Acetyl-l-Leucine-Polyethyleneimine-Mediated Delivery of CpG Oligodeoxynucleotides 2006 Inhibits RAW264.7 Cell Osteoclastogenesis
    Huining Wang, Wenwen Yu, Hongyan Li, Yi Zheng, Zhen Chen, Hongbing Lin, Yuqin Shen · 2020 · Drug Design Development and Therapy
83. Targeting the Toll-System in Cardiovascular Sciences
    Gábor Földes, Stephan von Haehling, Ewa Anita Jankowska, Stefan D. Anker · 2007 · Recent Patents on Inflammation & Allergy Drug Discovery
84. Nucleic Acids as Adjuvants
    Kevin Edward Brown, Montserrat Puig, Lydia Asrat Haile, Derek D.C. Ireland, John Martucci, Daniela I. Verthelyi · 2018 · Wiley eBooks
85. Engineering of Immunoactive Hydrogels Complements Tumor-Treating Fields for Glioblastoma Therapy
    Yingzhao Shao, Dongchen Li, Zide Wang, Xiaomin Yang, Zehan Shang, Jinming Han, Zheng Li, Mei Mi, Chen Gao, Zongyao Lv et al. · 2026 · ACS Nano
86. ROLE OF CpG ODN IN CONCANAVALIN A-INDUCED HEPATITIS IN MICE
    Kazumichi Abe, Hiromasa Ohira, Hiroko Kobayashi, Tsuyoshi Rai, Hironobu Saito, Atsushi Takahashi, Yukio Sato · 2005 · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
87. Immunobiology of Prion Diseases
    Konstantinos Xanthopoulos, Dimitra Dafou, Ειrini Kanata, Theodoros Sklaviadis · 2017 · InTech eBooks
88. Vaccination to treat noninfectious diseases: surveying the opportunities
    Stephen W. Martin, Martin F. Bachmann · 2006 · Elsevier eBooks
89. Chapter 21 – Vaccination to Treat Noninfectious Diseases: Surveying the Opportunities
    Martin F. Bachmann, Monique Vogel · 2006 · Academic Press eBooks
90. Engineering Interfaces for Infection Immunity
    James D. Bryers, Kim A. Woodrow · 2011 · Elsevier eBooks
91. Aggregation-Induced Emission-Based Vaccine Improves Potential Antitumor Immunotherapy
    Yong Liang, Huanle Gong, Yan Li, Yinghao Lu, Xiaoqian Wu, Xiaoyan Zhang, Dan Ding, Xiaolong Tang, Qiyun Tang · 2021 · Journal of Biomedical Nanotechnology
92. Combinatorial design and development of biomaterials for use as drug delivery devices and immune adjuvants
    Latrisha K. Petersen · 2011
93. Prion Disease Therapy: Trials and Tribulations
    Valerie L. Sim, Byron W. Caughey · 2010 · Wiley eBooks
94. Immuntherapie des Pankreaskarzinoms
    Jonathan Ellermeier · 2013 · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)
95. Chapter 10 Prions
    Adriano Aguzzi · 2007 · Blue books of neurology
96. Design and Development of Recombinant Vaccines with Viral Properties
    Gerd Lipowsky, Martin F. Bachmann · 2011 · Wiley eBooks
97. Strategies for Prevention of Device‐Related Nosocomial Infections
    Tamilvanan Shunmugaperumal · 2010 · Wiley eBooks
98. Effect of Surface Chemistry on the Immune Responses and Cellular Interactions of Porous Silicon Nanoparticles
    Mohammad‐Ali Shahbazi · 2015 · Työväentutkimus Vuosikirja
99. Immunogenicity and immune function of the cellular prion protein.
    Jeremy Darryl Isaacs · 2007 · UCL Discovery (University College London)
100. Prion Diseases
     Adriano Aguzzi, Frank L. Heppner, Ingo M. Westner, Markus Glatzel · 2007 · Elsevier eBooks